12.80

4.49% +0.55

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is currently priced at $12.80, with a 24-hour trading volume of 369.57K. It has seen a +4.49% increased in the last 24 hours and a -1.77% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $12.22 pivot point. If it approaches the $13.01 resistance level, significant changes may occur.

Previous Close:

$12.25

Open:

$12.41

24h Volume:

369.57K

Market Cap:

$635.28M

Revenue:

Net Income/Loss:

$-71.90M

P/E Ratio:

-9.0748

EPS:

-1.4105

Net Cash Flow:

$-81.17M

1W Performance:

+12.68%

1M Performance:

-1.77%

6M Performance:

+65.16%

1Y Performance:

-6.30%

1D Range:

$12.41

$13.53

52W Range:

$5.85

$17.70

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

888-378-6240

Address

150 N. Radnor Chester Rd., Suite F200, Radnor

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MLYS's Discussions on Twitter

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

GlobeNewswire Inc.

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday

Benzinga

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

GlobeNewswire Inc.

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know

Zacks Investment Research

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

GlobeNewswire Inc.

Mineralys Therapeutics Inc Stock (MLYS) Financials Data

Mineralys Therapeutics Inc (MLYS) Net Income 2024

MLYS net income (TTM) was -$71.90 million for the quarter ending December 31, 2023, a -141.28% decrease year-over-year.

Mineralys Therapeutics Inc (MLYS) Cash Flow 2024

MLYS recorded a free cash flow (TTM) of -$81.17 million for the quarter ending December 31, 2023, a -177.79% decrease year-over-year.

Mineralys Therapeutics Inc (MLYS) Earnings per Share 2024

MLYS earnings per share (TTM) was -$2.02 for the quarter ending December 31, 2023, a +52.29% growth year-over-year.

Mineralys Therapeutics Inc Stock (MLYS) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648
Rodman David Malcom	Chief Medical Officer	Mar 12 '24	Option Exercise	1.08	6,348	6,856	55,631
Rodman David Malcom	Chief Medical Officer	Mar 11 '24	Option Exercise	0.54	5,017	2,709	49,283
Rodman David Malcom	Chief Medical Officer	Feb 12 '24	Option Exercise	0.84	11,366	9,566	44,266
Samsara BioCapital GP, LLC	10% Owner	Feb 12 '24	Buy	13.50	555,555	7,499,992	5,074,916
Rodman David Malcom	Chief Medical Officer	Jan 12 '24	Option Exercise	1.08	6,348	6,856	32,900
Rodman David Malcom	Chief Medical Officer	Jan 11 '24	Option Exercise	0.54	5,017	2,709	26,552
Rodman David Malcom	Chief Medical Officer	Dec 11 '23	Option Exercise	0.54	5,018	2,710	20,069
Congleton Jon	Chief Executive Officer	Nov 22 '23	Buy	5.97	4,250	25,356	1,049,068
Rodman David Malcom	Chief Medical Officer	Nov 13 '23	Option Exercise	0.54	5,017	2,709	15,051

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.